Guides & references
Summary of Canadian Immunization Committee (CIC) Recommendations for Human Papillomavirus Immunization Programs
On the basis of scientific evidence, the National Advisory Committee on Immunization (NACI) now recommends HPV immunization for males and females between 9 and 26 years of age for the prevention of HPV disease. In response to expanded indications for the quadrivalent HPV vaccine, as well as with the introduction of a new bivalent HPV vaccine, the Canadian Immunization Committee (CIC) considered the programmatic issues of the HPV vaccines and their appropriateness for inclusion in provincial and territorial routine immunization schedules. This document is a brief summary of the full CIC HPV recommendations.
Summary of the CIC Recommendations for zoster immunization programs
Surveillance accrue des méningococcies invasives au Canada, 2006-2011
L’objectif du présent rapport est de décrire l’épidémiologie de la méningococcie invasive au Canada de 2006 à 2011.
The Recommended Use of the Multicomponent Meningococcal B (4CMenB) Vaccine in Canada
The NACI Statement, presented as Part 1, and the programmatic chapters, presented as Part 2, have been combined together and are considered the Common Guidance for the recommended use of the multicomponent meningococcal B (4CMenB) vaccine in Canada.
Update on the Use of Herpes Zoster Vaccine
Since the development of the 2010 statement, new data has been published with regards to the administration and safety of herpes zoster vaccine. n order to inform the recommendations of the National Advisory Committee on Immunization (NACI) made in this update, a systematic review of the literature was undertaken. This review focused on emerging literature since the previous statement as well as specific areas highlighted for review. Articles were obtained using a PubMed search from August 31, 2008 to September 30, 2012. Recommendations and llevels of evidence evaluations were agreed to by consensus of NACI members and were based on previously published NACI guidelines.
Update on the Use of Pneumococcal Vaccines: Addition of Asthma as a High-Risk Condition
Current evidence indicates that asthma is a risk factor for invasive pneumococcal disease, even in the absence of prolonged systemic corticosteroid use or COPD. Pneumococcal infection can cause severe disease. The most effective way to prevent these infections is through immunization.
AMMI Canada Guideline - The use of antiviral drugs for influenza: A foundation document for practitioners
The purpose of this document is to provide information for clinicians on the use of antiviral drugs for the prevention and treatment of seasonal influenza. It is provided as a foundation document which, with brief supplements published as needed to describe new developments, is intended to replace the annual Guidance publications.
Guidelines for the Prevention and Control of Measles Outbreaks in Canada
The Guidelines for Control of Measles Outbreaks in Canada assist Canadian public health authorities in their investigation and management of measles outbreaks, in order to prevent complications as a result of measles infection and limit secondary spread of measles during an outbreak.
Lignes directrices pour la prévention et le controle des éclosions de rougeole au Canada
Les directives mises à jour ont été rédigées pour aider les autorités canadiennes de santé publique dans l’examen et la gestion des éclosions de rougeole afin de prévenir les complications des infections par le virus et de restreindre la propagation secondaire de la maladie en cas d’éclosion.
Healthcare Personnel Seasonal Influenza Immunization Program: Human Resource Planning Tool
A companion Toolkit to the ‘Successful Healthcare Personnel Influenza Immunization Programs’ Guide.